Here's why the NIB (ASX:NHF) share price is on the rise today

The NIB Holdings Limited (ASX: NHF) share price is continuing to ascend today on the back of another positive update. Here's the details.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is continuing to ascend on the back of another positive update.

At the time of writing, the private health insurer's shares are swapping hands for $6.31, up 1%.

wooden blocks with percentage signs being built into towers of increasing height

Image source: Getty Images

What did NIB announce?

Investors appear pleased with the company's strategic direction, pushing NIB shares higher in early morning trade.

In a statement to the ASX, NIB advised it has sold its digital healthcare directory platform, Whitecoat to Commonwealth Bank of Australia (ASX: CBA).

Along with other shareholders, NIB approved the terms of the sale yesterday.

As a result, the company expects to receive roughly $9 million in profit before tax on the sale of its shareholding in Whitecoat.

In the 8 years of operation, Whitecoat has grown to become Australia's largest digital healthcare services directory. Currently, the online platform features more than 300,000 healthcare providers for consumers to find, book, and pay for treatment. In 2018, Whitecoat expanded its market presence by offering its services to New Zealand.

NIB managing director, Mark Fitzgibbon commented on the sale:

The sale to CBA will lift critical mass and the "network effect" these kinds of platforms rely upon. It will also bring the level of investment required to further develop Whitecoat's technology.

Just as Elon Musk doesn't manufacture every component of a Tesla nor will we see single companies build monolithic end to end solutions in the world of digital healthcare. Like for Tesla, our job at nib is to assemble the best tech functionality into a seamless and integrated experience for our members and providers. There remains so much more to do.

Mr Fitzgibbon highlighted that NIB never considered Whitecoat as part of its core strategy. This is because the online platform leans towards healthcare provider payments as opposed to health insurance plans. Furthermore, he assured that the sold-off business represents just one of many components of its total digital ecosystem for consumers and healthcare providers.

About the NIB share price

NIB shares have been on fire lately, storming close to 20% since releasing its trading update and outlook for FY21. It's worth noting, the company's shares reached a fresh 52-week high of $6.28 yesterday, before some slight profit-taking occurred.

NIB has a market capitalisation of roughly $2.8 billion, with approximately 457.7 million shares on issue.

Motley Fool contributor Aaron Teboneras owns shares of NIB Holdings Limited. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »